Real-world use of PCSK9 inhibitors: A single-center experience
| Autor: | Marcel Zughaib, Sinan Sarsam, George Degheim, Abeer Berry, Robby Singh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Male Medicine (General) Clinical Research Reports Gene Expression 030204 cardiovascular system & hematology Single Center Biochemistry 0302 clinical medicine Risk Factors PCSK9 Inhibitors Hypolipidemic Agents lipid-lowering therapy Atherosclerotic cardiovascular disease atherosclerotic cardiovascular disease General Medicine Middle Aged Treatment Outcome 030220 oncology & carcinogenesis LDL cholesterol Drug Therapy Combination Female lipids (amino acids peptides and proteins) Proprotein Convertase 9 medicine.medical_specialty Heterozygote Statin medicine.drug_class PCSK9 inhibitor Hypercholesterolemia 03 medical and health sciences R5-920 Internal medicine medicine Humans Protease Inhibitors Risk factor Triglycerides Aged Retrospective Studies Ldl cholesterol business.industry Biochemistry (medical) Cholesterol HDL statin Cell Biology Cholesterol LDL medicine.disease Proprotein convertase Atherosclerosis Dyslipidemia Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Journal of International Medical Research, Vol 47 (2019) The Journal of International Medical Research |
| ISSN: | 1473-2300 0300-0605 |
| Popis: | Objective Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. We sought to investigate the impact of these medications in a real-world cardiology practice. Methods This was a retrospective study of 17 patients with either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) levels above the treatment target despite maximally tolerated statins. Baseline lipid profile was compared with a repeat lipid profile obtained 4 to 6 weeks after initiating treatment with a PCSK9 inhibitor. Results The average duration of PCSK9 inhibitor treatment was 10.7 months. Lipid profile comparison showed that total cholesterol decreased from 243 ± 72 to 148 ± 39 (mg/dL) (39% reduction), triglycerides decreased from 185 ± 86 to 149 ± 62 (mg/dL) (19.5% reduction), high-density lipoprotein cholesterol increased from 56 ± 20 to 62 ± 26 (mg/dL) (10.7% increase), and LDL-C decreased from 154 ± 30 to 57 ± 32 (mg/dL) (63% reduction) from baseline. Conclusions PCSK9 inhibitors as add-on therapy to maximally tolerated statins resulted in an approximately 63% reduction in LDL-C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|